Accessibility Menu
GelStat logo

GelStat(OTC) GSAC

Market Cap$1.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-98%
1 Year-25%
1 Month+0%
$0.00
+50.00%
+0.00Today
GelStat last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-04
GelStat stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-28
1 month+0%USD 0.002026-08-05
3 month+0%USD 0.002026-06-05
Year to date-14.29%USD 0.002025-12-31
1 year-25%USD 0.002025-09-04
3 year+20%USD 0.002023-09-05
5 year-98.25%USD 0.022021-09-03
Since inception-99.95%USD 0.602003-04-30

GelStat Financials at a Glance

Market Cap

$1.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$379.09K

Net Income (TTM)

-$278.06K

EPS (TTM)

-$0.00

P/E Ratio

-3.00

Dividend

$0.00

Beta (Volatility)

0.21 (Low)

Price

$0.00

Volume

3,449

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Apr 16, 2015

GSAC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GelStat

GelStat Corporation operates as a consumer healthcare enterprise, specializing in the innovation, formulation, and commercialization of over-the-counter (OTC) health solutions. The company offers a diverse product portfolio addressing various common health concerns, including migraine relief, weight management, energy boosting, and sleep assistance.

Products and Services
  • GelStat Migraine: A patented remedy targeting migraine headache pain
  • Chews 2 Lose: An appetite-controlling gum designed for weight management
  • GelStat Sleep: A solution intended to alleviate sleep disturbances
Growth Outlook
  • Recent quarterly revenue increased to $80,081, showing potential for growth
  • Gross profit margin improved to 86.37% in Q2 2025, indicating operational efficiency
  • Product diversification may enhance market reach and consumer engagement
Financial Highlights
  • Trailing twelve months (TTM) revenue of $246,620 reflects steady sales
  • Net income for Q2 2025 was -$99,982, highlighting ongoing challenges
  • Current ratio of 0.30 suggests liquidity concerns that need addressing
GelStat Corporation is positioned within the healthcare sector, focusing on innovative solutions for everyday health issues. The company’s product offerings are designed to meet consumer needs in a competitive market. Recent financial data indicates a mixed performance, with revenue growth in the latest quarter but ongoing net losses. The improvement in gross profit margin suggests that operational efficiencies are being realized, which could be a positive sign for future profitability. However, liquidity challenges indicated by the current ratio may require strategic management to ensure financial stability. Overall, GelStat Corporation presents a unique opportunity in the consumer healthcare space, with potential for growth through product innovation and market expansion.
AI Generated • Sep 5, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5

CEO

Javier G. Acosta

Website

www.gelstat.com

Headquarters

Palm City, FL 34990, US

GSAC Financials

Key Financial Metrics (TTM)

Gross Margin

88.25%

Operating Margin

-104.30%

Net Income Margin

-141.98%

Return on Equity

17.09%

Return on Capital

N/A

Return on Assets

-64.26%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.74B

Volume

3.45K

Avg. Volume

116.67K

Financials (TTM)

Gross Profit

$266.69K

Operating Income

-$430.82K

EBITDA

-$157.42K

Operating Cash Flow

-$39.70K

Capital Expenditure

$0.00

Free Cash Flow

-$39.70K

Cash & ST Invst.

$71.41K

Total Debt

$849.62K

GelStat Performance Analysis

GelStat annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,333-66.8%
20232023-12-31USD 149,5276309.2%
20242024-12-31USD 349,730133.9%
20252025-12-31USD 267,962-23.4%
GelStat sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-3050.5%
Q42024-12-31N/A
Q12025-03-31-45.0%
Q22025-06-3024.1%
GelStat annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.0033.3%
20232023-12-31USD -0.00-83.3%
20242024-12-31USD -0.00-50.0%
20252025-12-31USD -0.000.0%
GelStat sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31N/A
Q22025-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$80.08K

+2.8%

Gross Profit

$69.16K

+20.4%

Gross Margin

86.37%

N/A

Market Cap

$1.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$561.05K

N/A

Employees

2

N/A

Net Income

-$99.98K

-120.2%

EBITDA

-$62.18K

-526.5%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$71.41K

+182.1%

Total Debt

$849.62K

N/A

Accounts Receivable

$45.59K

N/A

Inventory

$0.00

N/A

Long Term Debt

$781.97K

N/A

Short Term Debt

$67.66K

N/A

Return on Assets

-64.26%

N/A

Return on Invested Capital

35.96%

N/A

Free Cash Flow

-$15.49K

+36.0%

Operating Cash Flow

-$15.49K

+36.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AOXGAoxing Pharmaceutical Company, Inc.
$0.00+0.00%
VDRMViaDerma, Inc.
$0.00+0.00%
SFLMSFLMaven Corp.
$0.00+0.00%
LRSVLink Reservations Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About GSAC

What is the current price of GelStat?

GelStat is trading at $0.00 per share.

What is the 52-week range for GelStat?

Over the past 52 weeks, GelStat has traded between $0.00 and $0.00.

How much debt does GelStat have?

As of the most recent reporting period, GelStat reported total debt of $853.41K.

How much cash does GelStat have on hand?

GelStat reported $3.96K in cash and cash equivalents in its most recent financial results.

What is GelStat’s dividend yield?

GelStat does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services